Repare Therapeutics Shareholders Approve Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Repare Therapeutics announced that its shareholders have approved the acquisition of all of the issued and outstanding common shares of the company by XenoTherapeutics and Xeno Acquisition Corp. by way of a statutory plan of arrangement at the special meeting of Shareholders held on January 16. The arrangement is subject to the approval of the Superior Court of Quebec and other customary closing conditions. The Court hearing for the final order to approve the Arrangement is expected to take place on January 23, and, assuming receipt of the approval of the Court and satisfaction of other customary conditions to closing, the completion of the arrangement is expected to occur on or about January 28.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RPTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RPTX
Wall Street analysts forecast RPTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPTX is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.650
Low
3.00
Averages
3.00
High
3.00
Current: 2.650
Low
3.00
Averages
3.00
High
3.00
About RPTX
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
- Credit Support: Galectin Therapeutics Inc. secured a $10 million credit line, ensuring funding to cover expected expenditures through March 2027, thereby enhancing its R&D capabilities in the NASH cirrhosis treatment space.
- FDA Guidance: The FDA provided written feedback on Galectin's regulatory pathway for belapectin, marking a significant advancement in the company's drug development efforts, which could expedite its product's market entry.
- Market Reaction: Galectin's stock rose by 1% to $4.03 in Wednesday's trading, reflecting investor optimism regarding its financing and FDA support.
- Strategic Implications: This credit line and FDA guidance will provide Galectin with essential funding and regulatory backing in the competitive biopharmaceutical market, aiding its future clinical trials and market launch efforts.
Continue Reading
Repare Therapeutics Surges 18.9% Leading Biotechnology Sector Gains
- Biotechnology Sector Strength: The biotechnology sector collectively rose by approximately 1.4%, with Repare Therapeutics leading the charge with an 18.9% increase, indicating strong market confidence in its growth potential, which may attract more investor interest.
- Greenwich LifeSciences Follows Suit: Greenwich LifeSciences saw its stock rise by about 16%, further enhancing the overall performance of biotechnology stocks, reflecting positive sentiment among investors and potential market opportunities in the sector.
- Market Sentiment Recovery: The robust performance of biotechnology stocks may signal a recovery in market sentiment, particularly after recent volatility, as investors reassess the value and growth prospects of the industry.
- Increased Investor Attention: As biotechnology stocks rise, investor attention is likely to increase, especially regarding new drug development and innovative technologies, potentially leading to more capital inflow into the sector.
Continue Reading